Aortic stenosis is the most common valvular heart disease in the elderly with increasing prevalence worldwide. Initially considered experimental, transcatheter aortic valve implantation (TAVI) has transitioned rapidly to the standard of care for many patients with severe symptomatic aortic stenosis (AS).
In the past five years, the CCS Transcatheter Aortic Valve Implantation (TAVI) Quality Committee has succeeded in engaging multidisciplinary and national stakeholders to join in the development and measurement of quality indicators and contribute to a national dialogue to optimize the care and health service delivery for patients with complex valvular heart disease. Together, we made significant advances to leverage the clinical, administrative and policy expertise across all Canadian centres and regions, and demonstrated the feasibility and power of promoting a culture of national commitment to excellence. The purpose of this workshop is to build on this early work initiated by CCS, and mark the beginning of the next phase in promoting the quality of TAVI in Canada and discussing the evolution of the quality indicators to mirror the expanding indications.
In 2019, the Canadian Cardiovascular Society will be publishing its second position statement for TAVI in the Canadian Journal of Cardiology. This workshop will update the cardiovascular community on the content and recommendations stemming from that panel, with several members of the primary panel participating. This workshop will summarize the results of the 2019 Quality Report and recommendations from the 2019 CCS TAVI Position Statement and will provide an excellent opportunity for discussion with national leaders in TAVI.